Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study
- 31 January 2002
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 84 (1) , 32-35
- https://doi.org/10.1006/gyno.2001.6441
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Current status of pyrazoloacridine as an anticancer agentInvestigational New Drugs, 1999
- Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1998
- Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinomaInvestigational New Drugs, 1998
- Phase II study of pyrazoloacridine in patients with advanced colorectal carcinomaCancer Chemotherapy and Pharmacology, 1997
- Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.Journal of Clinical Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsBritish Journal of Cancer, 1989
- Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agentGynecologic Oncology, 1985